मातृ एवं शिशु स्वास्थ्य में क्लिनिक

अमूर्त

Commentary on Efficacy and Safety of Trabectedin in Metastatic Uterine Leiomyosarcoma: A Retrospective Multicenter Study of the Spanish Ovarian Cancer Research Group (GEICO)

Maria Jesus Rubio

Uterine Leiomyosarcoma (uLMS) is a very rare and aggressive carcinoma which, at advanced or recurrent stage, has a median overall survival of below 12 months. The Spanish ovarian cancer research group (GEICO), carried out a retrospective, observational, multicenter study involving 36 adult patients with unrespectable advanced or metastatic uLMS who received trabectedin after an anthracycline-containing regimen. The efficacy and safety observations found with trabectedin in this study were in line with previously shown in clinical trials.

Trabectedin provides long-term carcinoma stabilization and adequate tolerability, thus it represents an appropriate option for the treatment of advanced uLMS. Beneficial effects are optimized when administered as second-line, after the failure of the anthracycline-containing regimen, which allows achieving longer clinical benefit and disease control. Furthermore, it is recommended to maintain the treatment with trabectedin until disease progression due to its better efficacy outcomes as well as its safety profile, allowing the long-term administration with no cumulative toxicities. Trabectedin has also demonstrated activity in diverse soft tissue sarcoma subtypes.